Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune ...
GERMANTOWN, MD / ACCESS Newswire / September 17, 2025 / uBriGene Biosciences, a leader in CGT CDMO and iPSC manufacturing ...
The progress in induced pluripotent stem cells (iPSCs) and organoid technology has addressed the lack of suitable in vitro models for human neurodevelopmental and degenerative disorders. Over the past ...
Shares of Century Therapeutics, Inc. (IPSC) have gained 9.7% over the past four weeks to close the last trading session at $5, but there could still be a solid upside left in the stock if short-term ...
This article is based on a poster originally authored by Malika Bsibsi, A. Popalzij, Matteo Zanella, Lieke Geerts, Mark Musters, Inês Ferreira, Stefan Kostense, David F. Fischer and Marijn Vlaming, ...
Century Therapeutics, Inc. (IPSC) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates - ...
Basic fibroblast growth factor (bFGF) is essential for sustaining pluripotency and enabling lineage-specific differentiation during induced pluripotent stem cell (iPSC) research workflows. In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback